JASPER THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
JASPER THERAPEUTICS, INC. (JSPR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 50.00 thousand shares for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-11.
Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2023-08-11
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-03-31 was 50.00K shares, a 98.47% decline year-over-year.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was 315.00K shares.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-06-30 was 332.89K shares.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 145.75K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 50.00K shares 10-Q · filed 2023-08-11 | ||
| 2023-03-31 | 50.00K shares 10-Q · filed 2023-05-12 | |||
| 2022-09-30 | 315.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 647.89K shares derived: sum of 2 quarters · filed 2022-11-10 | 3.92M shares 10-Q · filed 2022-11-10 | 3.92M shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 332.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 3.60M shares 10-Q · filed 2022-08-12 | 3.60M shares derived: sum of 3 quarters · filed 2022-08-12 | |
| 2022-03-31 | 3.27M shares 10-Q · filed 2022-05-12 | 3.27M shares derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | 145.75K shares 10-K · filed 2022-03-18 | ||
| 2021-09-30 | 145.75K shares 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |